Latest From Valneva SE
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.
Valneva’s 2019 guidance has been boosted by the US Army’s Ixiaro vaccine order, as other products flourish in the pipeline.
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
A European/US company collaboration has reported encouraging safety and immunogenicity in early clinical studies with an alum-adjuvanted Zika vaccine based on inactivated whole virus.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Valneva SE
- Senior Management
Thomas Lingelbach , Pres. & CEO
David Lawrence, CFO
Franck Grimaud, CBO
Wolfgang Bender, MD, PhD, CMO
- Contact Info
Phone: (33) 2 28 07 37 10
Campus Bio-Ouest | 6, Rue Alain Bombard
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.